# Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours

> **NCT04808362** · PHASE1,PHASE2 · TERMINATED · sponsor: **Peptomyc S.L.** · enrollment: 22 (actual)

## Conditions studied

- Advanced Solid Tumors
- Pancreatic Cancer
- CRC

## Interventions

- **BIOLOGICAL:** OMO-103

## Key facts

- **NCT ID:** NCT04808362
- **Lead sponsor:** Peptomyc S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-28
- **Primary completion:** 2022-12-15
- **Final completion:** 2023-01-11
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Phase 1completed; sponsor decided to change strategy to a combination study
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04808362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04808362, "Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04808362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*